Kay Rowe, an author and freelance writer, has expressed concerns regarding the 340B Drug Pricing Program, stating that most patients do not benefit from the intended discounts. This statement was made on X.
“Most patients never see a discount from the 340B program,” said Rowe, Author and Writing Coach.
The 340B Drug Pricing Program, established in 1992 and overseen by the Health Resources and Services Administration (HRSA), allows eligible healthcare providers to purchase outpatient drugs at reduced prices. The program’s primary aim is to assist providers in maximizing limited resources to serve more patients, especially those who are uninsured or from low-income backgrounds. Its broader objective is to improve access to affordable medications and comprehensive healthcare services for vulnerable populations.
According to the American Hospital Association, hospitals involved in the 340B program use savings from discounted drug purchases to fund essential services. These services include providing free or reduced-cost medications, expanding access to care, and supporting community outreach programs. The reinvestment of these savings is intended to strengthen healthcare delivery in underserved areas.
Pharmaceutical Research and Manufacturers of America (PhRMA) reported that in New York, 113 hospitals participate in the 340B program with over 6,000 contracts with pharmacies nationwide. However, only 24% of these contract pharmacies are situated in medically underserved areas, while 86% of participating hospitals offer below-average levels of charity care. This discrepancy has raised questions about the program’s effectiveness in reaching its intended beneficiaries within the state.
Rowe is based in Colorado and operates under Embrace Life LLC. She has self-published memoirs detailing her personal experiences, including “A Pawn in the Scientology Money Machine” (2017) and “Belonging- My Transformation to a Cult-Free Life” (2023). In addition to writing, she is a certified mediator and licensed real estate agent.
